GlassScriptPhysician profile
Yuchun Han
NPI 1053307041
$50,152.59
in general payments reported to CMS, 2019-2025
57 companies · $2,418 in 2025
The $2,418 reported for 2025 was more than what 76% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,006 · 2020: $23K · 2021: $12K · 2022: $4,615 · 2023: $3,072 · 2024: $3,172 · 2025: $2,418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,662.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,662.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $24,267.17 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $5,384.85 | 2020-2021 | |
| Ucb, INC. | $2,494.91 | 2019-2025 | Briviact, Nayzilam, Fintepla |
| Neurelis, INC. | $1,802.38 | 2020-2025 | Valtoco |
| Sunovion Pharmaceuticals INC. | $1,360.17 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $1,317.67 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Upsher-Smith Laboratories LLC | $894.69 | 2019-2023 | |
| Celgene Corporation | $875.16 | 2021-2025 | Zeposia |
| Lundbeck LLC | $874.43 | 2019-2025 | Vyepti |
| Abbvie INC. | $855.44 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $818.88 | 2020-2025 | Ingrezza, Ongentys |
| Biogen, INC. | $807.12 | 2019-2025 | Vumerity, Tysabri |
| Sk Life Science, INC. | $802.49 | 2020-2025 | |
| Eisai INC. | $765.53 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $706.35 | 2019-2024 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yuchun Han listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.